This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TheDeal: KKR Invests $200 Million in India's Gland Pharma

NEW YORK (TheDeal) -- New York buyout firm Kohlberg Kravis Roberts & Co.  (KKR - Get Report) has agreed to take a minority stake in generic drugs maker Gland Pharma Ltd, paying $200 million in what is reportedly the biggest ever private equity investment in the Indian subcontinent's health care sector.
 
The investment includes an injection of new money and also provides for a full exit for Evolvence India Life Sciences Fund. The seller is a Mauritius-based investment vehicle of Dubai's alternative assets manager Evolvence Capital.


It was not immediately clear whether another existing investor, pre-filled syringes specialist Vetter Pharma International GmbH, of Ravensburg, Germany and Stokie, Ill., is also selling all or part of its stake. Gland Thursday, Nov. 28, thanked the Vetter family for "inspiring" the company in the niche field in which both work.
Hyderabad-based Gland Pharma develops and manufactures generic injectable pharmaceuticals, primarily for the U.S. market. Established in 1978, it says it was the first Indian company to receive Food and Drug Administration approval for injectable liquids. It also pioneered Heparin technology in India.

As well as Heparin and other anti-coagulants, it manufactures active pharmaceutical ingredients and injectable formulations for conditions including osteoarthritis and areas including gynecology and ophthalmology.
 
Gland said it will use KKR's investment for product development, as well as growing its manufacturing base.  
"Our partnership with KKR will help us in our next phase of growth, as we look to materially expand our manufacturing capacities and invest more in our development work," Gland Pharma founder and chairman Ravi Penmetsa said in a statement.
Gland Pharma is KKR's second investment in India in 2013. The previous investment was the acquisition of a controlling stake in Alliance Tire Group from Warburg Pincus LLC, in a deal valued at $650 million. It is also the fourth investment from its KKR Asian II Fund.
 By Jonathan Braude for TheDeal

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
KKR $23.39 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs